RecruitingPhase 2NCT07591090

A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer

A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of AK146D1 Combined With AK112 in Patients With Advanced Breast Cancer

Sponsor

Akeso

Enrollment

200 participants

Start Date

Jul 17, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Breast Cancer

Summary

This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 combined with AK112 in advanced breast cancer.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AK112 Injection and a drug called AK146D1 for injection for people with advanced breast cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.